Sebastián Mendoza Cabana.

Medico Urólogo.
Urología Oncológica
Montería, Córdoba, Colombia

[Michael Hofman @DrMHofman]

Controversial then, settled now: I remember when PSMA PET/CT was not recommended - concern of Will Roger's "Stage Migration".

Now, 95% of the international panel agreed that PSMA PET/CT should be the staging tool in high-risk prostate cancer (strong consensus), and 85% would not substitute whole-body MRI for it.

From investigational to unanimous #ProPSMA

The flip side is just as important. Zero of 18 questions on monitoring metastatic disease reached consensus. More evidence is needed.

@APCCC_Lugano Diagnostics 2025 is out in @EUplatinum:
https://t.co/fgI12Lc7uW

[European Urology Oncology @EurUrolOncol]

Latest Article Online!
Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non–muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients by Mehdi Kardoust Parizi...Shahrokh F. Shariat et al
https://t.co/vvguAJWNRq

Thank you to the authors for trusting EUO with your work!

@Mehdi_Kardoust
@uroweb
@mroupret
@GPloussard
@jteoh_hk
@Ric_Campi
@CaPsurvivorship
@LauraMarandino
@RenuEapen
@Ecastromarcos
@OncoAlert
@Sciencedirect

[European Urology @EUplatinum]

📢 New publication in European Urology
We are pleased to highlight a new study published in European Urology, titled “Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial”.

👏 Congratulations to Hiroshi Kitamura, Tsukamoto T., and Nishiyama H. on this excellent contribution, together with all co-authors.

🔗 Read the full article here:
👉 https://t.co/St9i7pi2nX

#EuropeanUrology #Urology #UroOncology #Research #MedicalResearch #AcademicUrology

[European Urology @EUplatinum]

📢 New publication in European Urology
We are pleased to highlight a new study published in European Urology, titled “SPARC: The Standardised Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Analysis and Reporting Consensus: A Delphi Analysis”.

👏 Congratulations to @ProfKHerrmann, @Walzjc, and @bjartell on this excellent contribution, together with all co-authors.

🔗 Read the full article here:
👉 https://t.co/fR0CCbgkjD

#EuropeanUrology #Urology #UroOncology #Research #MedicalResearch #AcademicUrology

[FLoscoMD @fedelosco]

¿Puede la IA reducir las inequidades en cáncer en #LATAM
@ASCO 2026 conversaciones sobre privacidad, transparencia, y el futuro de la #IA en oncología.
La tecnología avanza rápido. El desafío es implementarla de forma ética y segura.
https://t.co/XzpSGYJgEF

[Diego Barreiro @DBarreiro4]

Costo de un año de tratamiento con ARPIS. Puede latinoamérica afrontar estos costos?

Annual cost of ARPI therapy: Can Latin America sustainably afford these costs?”

@APCCC_Lugano

[Jeff Ryckman @jryckman3]

1/ 🚨 New @NEJM: Perioperative enfortumab vedotin + pembrolizumab (EV+pembro) in MIBC (KEYNOTE-905)

Congrats to the authors on an important randomized phase 3 trial in a tough, cisplatin-ineligible population 👏

Let’s walk through it 👇

[Dr Rishabh Jain @DrRishabhOnco]

🚨 ASCO GU 2026
Top 15 Clinical Trials to Watch
#GU26

🔵 Prostate Cancer
|Precision & Intensification

🧪 CIPHER
Testing platinum as a low-cost option in HRR-mutated mCRPC

☢️ PSMAaddition
¹⁷⁷Lu-PSMA-617 moves into mHSPC

🎯 PEACE-2
Systemic intensification (abiraterone + ADT) with definitive prostate RT

🔗 PEACE-3
Radioligand + ARPI combination in mCRPC

🧬 CAPItello-281
AKT pathway targeting in PTEN-deficient mHSPC

🟢 Bladder & Urothelial Cancer
| ADCs & Bladder Preservation

🧬 KEYNOTE-B15 / EV-304
Perioperative EV + pembrolizumab as a new backbone in MIBC

🧪 VOLGA
IO–ADC triplet strategy in perioperative MIBC

🫙 SunRISe-2
Bladder-sparing TAR-200 + cetrelimab in BCG-unresponsive NMIBC

🧫 Disitamab vedotin + pembrolizumab
ADC expansion beyond enfortumab in HER2-expressing disease

🩸 RETAIN trials (LBA632)
ctDNA-guided, response-adapted bladder preservation in MIBC

🟡 Renal Cell Carcinoma
| Post-IO Sequencing

🧪 LITESPARK-011
Belzutifan combinations after IO–TKI failure

🛡️ LITESPARK-022
HIF-2α inhibition enters the adjuvant setting

🔁 TiNivo-2
IO rechallenge tested rigorously

💊 STELLAR-001
Next-generation TKI (XL092) strategies

🔪 CYTOSHRINK
Response-adapted cytoreductive nephrectomy after systemic therapy

#ASCOGU26 #GUOncology #OncoTwitter #MedTwitter
@OncoAlert @myesmo @esmo_open @asco @Larvol

[Luis Rico @luisrico89]

Proud to share the first systematic review on the use of drug-coated balloons for ureteral strictures. After great work by the EAU @Uroweb Endourology Section, it’s finally published in @wjurol
Let’s keep sharing and generating results to strengthen the current evidence.

[Luis Rico @luisrico89]

Very happy to share our new scientific study: Is direct in-scope suction (DISS) the solution for non-prestented and sheathless flexible ureteroscopy? @SpringerNature
Finding a new scenario for #DISS and exploring the best indications for each procedure

[Luis Rico @luisrico89]

A full week of scientific activity: discussing, learning, and sharing fascinating topics in #ENDO
Grateful for the exchange of ideas and the passion for advancing our field!
#OEHA2025 & 40 Jornadas Medicos Residentes @hpcmdp
Thank you @DrAGonzalez21 for the kind invitation

[Luis Rico @luisrico89]

Excited to share our team’s new study on emerging laser technologies⚡️
Clinical outcomes show strong similarities between Ho:YAG Magneto 🧲 and TFL @quanta_system highlighting how innovation continues to refine endourology practice.
#LaserTechnology #Endourology #FANS #Research

[Advanced Prostate Cancer Consensus Conference @APCCC_Lugano]

Rectal Swab–based Targeted Prophylactic Antibiotics Reduce Infectious Complications After Transrectal Prostate Biopsy

https://t.co/7k4oQUTqNi

In this systematic review and meta-analysis of nine randomized controlled trials including 3,002 patients, the use of targeted prophylactic antibiotics (TPAs) based on rectal swab cultures before transrectal ultrasound-guided prostate biopsy (TRUS-PB) was associated with a significant reduction in postbiopsy febrile urinary tract infections compared with empiric antibiotic prophylaxis (2.7% vs 5.2%; risk ratio 0.54, p = 0.003). The number needed to treat to prevent one febrile infection was 40. However, no significant difference was observed in the incidence of sepsis between the two groups.

These findings support incorporating rectal swab–guided antibiotic selection into prebiopsy protocols to reduce infection risk in patients undergoing TRUS-PB, though further research is warranted to clarify its impact on sepsis prevention. #ProstateCancer

Ichiro Tsuboi
@Mehdi_Kardoust
@fazekasMD
@miszczyk_marcin
@A_Cormio
@K_Tatsushi
@kensuke_bekku
@PiotrChlosta
@Albert0Briganti
@DrShariat

@OncoAlert 🚨
@Silke_Gillessen
@AOmlin
@nataliagandur
@bavilima

[Diego Barreiro @DBarreiro4]

@OncBrothers @costplusdrugs @mcuban @JCOGO_ASCO @neerajaiims @SuyogCancer @Prasshmehta @BijoyTelivala @AlanBryce9 @TiansterZhang @dr_yakupergun @DrYukselUrun @KekoaMDPhD @DrChoueiri LOW COST ABIRATERONE

https://t.co/ZKG2P6d6zF

[Oncology Brothers @OncBrothers]

Abiraterone 250mg vs. 1000mg? Multiple studies continue to show similar efficacy and ⬇️ cost (though through @costplusdrugs @mcuban, cost has gone ⬇️ significantly…), should the lower dose be the SoC in CRPC and higher dose be used as a back-up?

#OncTwitter #gusm @JCOGO_ASCO

[Gustavo @gusviani]

🔥 PCS-9: SBRT + ENZA Doubles Disease Control in Oligometastatic CRPC @OncoAlert @dr_cury

🎯 Objective
• Evaluate whether adding SBRT to ADT + enzalutamide ⬆️ outcomes in oligometastatic CRPC (≤5 mets)

🏥 Methods
• Ph 2, randomized, 13 Canadian centers.
• 100 men with oligometastatic CRPC
• Arm A: ADT + ENZA;
Arm B: ADT + ENZA + SBRT
• SBRT: 24–60 Gy in 2–8 fractions to all metastatic sites

📊 Results
• Median rPFS: 4.6 vs 2.3 y (HR 0.48; p=0.014)
• Time to next systemic therapy: 5.1 vs 2.9 y
• No grade 4/5 events; toxicity comparable

➡�� SBRT + ENZA marks a paradigm shift in oligometastatic CRPC management

[Luis Rico @luisrico89]

We continue working on such an important topic: #laser #laserperformance #efficacy #efficiency & #energyconsumption
TFL vs VT Ho:YAG technology
Another #laser study of our team in the prestigious @wjurol
@PabloNContreras @LorenaBanda13 @uropizza
doi:10.1007/s00345-025-05852-6

[Luis Rico @luisrico89]

2days of amazing #ENDO
We are honored to host in 🇦🇷 the #EAUEndourology section @Uroweb
Thank you very much @OTRAXER @endouro @LaurianDragos @BernardoNor9 @MSGONZALEZURO all the moderators and all those who joined us @PabloNContreras @LorenaBanda13

[Pablo Contreras @PabloNContreras]

LATINOS DEL MUNDO 🔥🔥🔥

MasterClass EAUEndoAR🇦🇷

Line Up @OTRAXER @endouro @LaurianDragos @BernardoNor9 @MSGONZALEZURO @luisrico89 @LorenaBanda13

🗓️August 1st. and 2nd. 2025

🏥Hospital Alemán @HAlemanBsAs 🇦🇷

Join Us for Sharing Knowledge 📚 + Impressive Networking 🤝

Live streaming 🌎🌍🌏, Spanish + English 🎧

📩Contact us: [email protected]

@Uroweb @SauUrologia @CAU_URO @ResidentesCAU @Endo_Society @young_endosoc @SIU_urology

[Luis Rico @luisrico89]

SAVE THE DATE 📆
🇦🇷 host the #EAUEndourology @Uroweb
@OTRAXER @endouro @LaurianDragos
@MSGONZALEZURO @BernardoNor9